Improving the clarification, characterization, and homogeneity of animal serum through Nanotrap nanoparticle technology

项目摘要 SARS-CoV-2是导致当前2019冠状病毒病（COVID-19）爆发的β-冠状病毒。大- 大规模诊断检测和大规模筛查是控制疫情的关键工具， 对于像SARS-CoV-2这样的传染病很重要。虽然各种临床上的药物-如血液， 咽拭子、唾液、肛门拭子和尿液--已经表明在感染患者中存在病毒， 由于唾液样品易于在家收集， 收藏潜力和适应性。尽管有这些优点，但SARS-CoV-2 RNA、抗原或 唾液样本中的病毒是可变的，范围从30%到100%的灵敏度，这是由于唾液是一种复合物， 生物溶液这种高变异性也意味着几乎所有的细胞都倾向于存在高背景信号。 分子分析测试，这混淆了准确的测试和快速跟踪能力。为了满足这一需求， Ceres Nanosciences提出了一个有竞争力的1年补充到其现有的第一阶段SBIR赠款 （1 R43 GM 135943; 02/01/2020-10/31/2020; NIGMS）测试使用其专有和专利的可行性 Nanotrap®技术可显著改善现有唾液样本中SARS-CoV-2的检测 目前市场上的分子诊断分析。这一补充目标福尔斯属于正在进行的 资助的项目，该项目正在评估使用Nanotrap颗粒来改善普通提取的可行性。 污染物-包括病毒-来自牛血清。补充工作将采用类似的工作流程， 评估利用Nanotrap颗粒和工作流程的可行性，以成本和时间有效地筛选小 以及大量的唾液和生物库全血和血清样本，以检测SARS-CoV的存在， 2病毒或抗体。

PROJECT SUMMARY SARS-CoV-2 is the β-coronavirus causing the current coronavirus disease 2019 (COVID-19) outbreak. Large- scale diagnostic testing and large-scale screening are key tools used to contain outbreaks, and are especially important for something as transmissible as SARS-CoV-2. While various clinical specimens—like blood, pharyngeal swabs, saliva, anal swabs, and urine—have showed the presence of the virus in infected patients, there has been a recent gravitation towards the use of saliva samples due to their ease of collection, at-home collection potential, and adaptability. Despite these advantages, the detection of SARS-CoV-2 RNA, antigen, or virus in saliva samples is variable, ranging from 30% to 100% sensitivity, due to the fact that saliva is a complex biosolution. This high variability also means that there tends to be a high background signal for almost all molecular assays tested, which obfuscates accurate testing and rapid tracking capabilities. To address this need, Ceres Nanosciences proposes a competitive 1-year supplement onto its existing Phase I SBIR grant (1R43GM135943; 02/01/2020–10/31/2020; NIGMS) to test the feasibility of using its proprietary and patented Nanotrap® technology to significantly improve the detection of SARS-CoV-2 from saliva samples using existing molecular diagnostics assays on the market today. This supplemental aim falls within the scope of the ongoing funded project, which is evaluating the feasibility of using Nanotrap particles to improve the extraction of common contaminants—including viruses—from bovine serum. The supplemental work will apply a similar workflow to evaluate the feasibility of leveraging Nanotrap particles and workflow to cost- and time-effectively screen small and large volumes of saliva and biobanked whole blood and serum specimens for the presence of SARS-CoV- 2 virus or antibody.